Navigation Links
India's Breast Cancer Drug Market Will Almost Double by 2012
Date:12/10/2008

Indian Physicians Start to Incorporate Targeted Therapies to Achieve Better Efficacy and Toxicity Profiles Than Conventional Therapies, According to a Report From Decision Resources

WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian breast cancer drug market will almost double from $35 million in 2007 to $64 million by 2012. According to the new Emerging Markets report entitled Breast Cancer in India, this growth will be fueled by rising disease prevalence, increasing wealth and growing disease awareness.

The report finds that docetaxel (Sanofi-Aventis's Taxotere, Indian products) and epirubicin (Pfizer's Farmorubicin, Indian products) will continue to be the market leaders, but sales of trastuzumab and bevacizumab (Roche's Herceptin and Avastin), gemcitabine (Eli Lilly's Gemcite, Indian products), and capecitabine (Roche's Xeloda, Indian products) will grow rapidly during this period.

The report also finds that Indian physicians in the six surveyed regions (Delhi, Mumbai, Bangalore, Chennai, Jaipur and Lucknow) are encouraged by the success of targeted therapies in other major markets and have started to increasingly incorporate targeted therapies --- Herceptin, Avastin, GlaxoSmithKline's Tykerb --- into breast cancer treatment to achieve better efficacy and toxicity profiles than conventional therapies. However, premium prices are the major constraint for market uptake.

"India's fast-growing economy will drive demand for novel therapies with higher efficacy and fewer side effects, which usually command high prices, among the burgeoning middle class and higher-income breast cancer patients," added Jing Wu, analyst at Decision Resources.

EMERGING MARKETS REPORTS

The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                          Elizabeth Marshall
    Decision Resources                       Decision Resources, Inc.
    781-296-2691                             781-296-2563
    nmorales@dresources.com                  emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar ... at 1:00 PM ET. A recording of the webinar will also be made available ... Home health and hospice companies are still popular targets for healthcare investors. This highly ...
(Date:3/29/2017)... North Hollywood, CA (PRWEB) , ... March 29, 2017 , ... ... and Northridge , is now offering laser dental treatments. Dental lasers are safe ... treatments. Laser dentistry expands patients’ options and can improve the overall quality of care. ...
(Date:3/29/2017)... , ... March 29, 2017 , ... The Wharton School ... and Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... opportunity that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... first technology to directly address the resolution to globally reduce the harmful use ... patented compound of FDA and TTB approved ingredients that when infused into alcohol, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... AMSTERDAM , March 29, 2017   ... global leader in health technology, and PathAI, a ... are collaborating with the aim to develop solutions ... diagnosis of cancer and other diseases. The partnership ... pathology, enabling this form of artificial intelligence to ...
(Date:3/29/2017)... Michigan , USA, March 29, 2017 ... Company that Cares by People magazine, in partnership with ... of 50 companies on the list. This list highlights ... that have succeeded in business while also demonstrating respect, ... the environment.  To determine the companies ...
(Date:3/29/2017)... , March 29, 2017 On March 28, the ... treat adult patients with relapsing forms of multiple sclerosis ... the first drug approved by the FDA for PPMS. ... care professional.  "Multiple sclerosis can have ... Billy Dunn , M.D., director of the Division of ...
Breaking Medicine Technology: